Home β€Ί Stock analysis β€Ί ZYBT

Zhengye Biotechnology (ZYBT) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)

Updated Oct 16, 2026, 4:00 PM ET

What changed since yesterday

ZYBT slides 6.7% to $1.40. Closed at $1.40, -6.67% vs the prior close of $1.50. Day range $1.38–$1.57, opened at $1.50.

Last close$1.40-6.67%
Day range1.38–1.57
Open1.50
Volume81.29K
52-week range0.62–8.01
Avg volume (20d)1.73M

ZYBT daily analysis β€” what happened

A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.

Oct 16, 2026 β€” ZYBT slides 6.7% to $1.40
Oct 15, 2026 β€” ZYBT dips 2.0% to $1.50
Oct 14, 2026 β€” ZYBT jumps 3.4% to $1.53
Oct 13, 2026 β€” ZYBT slides 12.4% to $1.48
Oct 12, 2026 β€” ZYBT dips 2.3% to $1.69
Oct 9, 2026 β€” ZYBT jumps 50.4% to $1.73, a 1-month high on 16.3x normal volume
Oct 8, 2026 β€” ZYBT dips 0.9% to $1.15
Oct 7, 2026 β€” ZYBT jumps 4.5% to $1.16
Oct 6, 2026 β€” ZYBT slides 6.7% to $1.11, a 1-month low, 3 down days in a row
Oct 5, 2026 β€” ZYBT slides 4.0% to $1.19, a 1-month low
Oct 2, 2026 β€” ZYBT dips 1.6% to $1.24

ZYBT latest news & SEC filings

Every SEC filing by or about ZYBT in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.

Aug 6, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001213900-26-086146

Jul 21, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001213900-26-080010

Jun 25, 2026 Β· Form 3 β€” New insider holdings

Initial insider ownership statement (Form 3) β€” a new director, officer or 10% owner disclosed their holdings

Source: SEC EDGAR filing 0001213900-26-071870

Jun 25, 2026 Β· Form 3 β€” New insider holdings

Initial insider ownership statement (Form 3) β€” a new director, officer or 10% owner disclosed their holdings

Source: SEC EDGAR filing 0001213900-26-071868

Jun 25, 2026 Β· Form 3 β€” New insider holdings

Initial insider ownership statement (Form 3) β€” a new director, officer or 10% owner disclosed their holdings

Source: SEC EDGAR filing 0001213900-26-071867

Jun 25, 2026 Β· Form 3 β€” New insider holdings

Initial insider ownership statement (Form 3) β€” a new director, officer or 10% owner disclosed their holdings

Source: SEC EDGAR filing 0001213900-26-071866

Jun 25, 2026 Β· Form 3 β€” New insider holdings

Initial insider ownership statement (Form 3) β€” a new director, officer or 10% owner disclosed their holdings

Source: SEC EDGAR filing 0001213900-26-071865

Things to know before you trade ZYBT

ZYBT market data (last 20 sessions)

DateOpenHighLowCloseVolume
Oct 16, 20261.501.571.381.4081.29K
Oct 15, 20261.501.661.481.5067.70K
Oct 14, 20261.451.721.441.53255.30K
Oct 13, 20261.431.751.431.48425.30K
Oct 12, 20261.821.851.381.692.93M
Oct 9, 20261.192.891.121.7330.60M
Oct 8, 20261.131.171.121.1510.30K
Oct 7, 20261.091.181.091.1631.70K
Oct 6, 20261.111.201.111.1144.40K
Oct 5, 20261.231.271.181.1914.60K
Oct 2, 20261.261.261.201.2415.90K
Oct 1, 20261.201.291.201.2613.80K
Sep 30, 20261.261.261.201.2013.80K
Sep 29, 20261.291.371.241.2420.50K
Sep 28, 20261.311.371.261.3010.00K
Sep 25, 20261.291.351.261.3019.30K
Sep 24, 20261.301.371.301.318.80K
Sep 23, 20261.281.381.281.3728.30K
Sep 22, 20261.351.351.261.2824.40K
Sep 21, 20261.341.381.341.3517.60K

About Zhengye Biotechnology

Zhengye Biotechnology (ZYBT) is listed on the Nasdaq and classified by the SEC under β€œPharmaceutical Preparations”. Its business address is in JILIN. State of incorporation: China. Fiscal year ends β€”. SEC CIK 1975641.

ZYBT board of directors & executives

From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).

Directors

NameRoleLatest filing
Zhenfa HanDirectorJun 25, 2026
Qiyi HuDirectorApr 24, 2026
Ping (Piji) JiangDirectorJun 25, 2026
Guohan (Nmn) LiDirectorApr 24, 2026
Wenhua SunDirectorMar 18, 2026

Executive officers

NameTitleLatest filing
Yuhong (Nmn) ChengVice General ManagerJun 25, 2026
Aiden HanCo-Chief Executive OfficerMar 18, 2026
Wei LianVice General ManagerMar 18, 2026
Zhongyao LiuChief Operating OfficerMar 18, 2026
Songlin SongCo-Chief Executive OfficerJun 25, 2026
Ping (Nmn) WangChief Financial OfficerJun 25, 2026

Recent insider buys & sales

DateInsiderTypeSharesPrice
No open-market insider buys or sales reported in the last 12 months.

ZYBT financials (annual, from XBRL filings)

Fiscal year endRevenueNet incomeDiluted EPSOperating cash flow
No annual XBRL figures available (foreign filers often report on Form 20-F).

Latest balance sheet: total assets $β€”, total liabilities $β€”, cash $β€”.

ZYBT earnings / results-day log

DateFilingClose that day
No 8-K earnings releases in recent filings.

Related stocks Β· Pharmaceutical Preparations

Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)

Popular today

Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)

More on ZYBT

Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.